ReviewViruses2020
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 6 syntheses or guidelines pooled it, 428 citations in OpenAlex.
- AI-driven techniques for detection and mitigation of SARS-CoV-2 spread: a review, taxonomy, and trends.Clinical and experimental medicine · 2025Pooled it
- Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review.Reviews in medical virology · 2021Pooled it
- Pooled it
- Recent advances in the diagnosis of COVID-19: a bird's eye view.Expert review of molecular diagnostics · 2021Pooled it
- Kawasaki-like disease in children with COVID-19.Rheumatology international · 2020Pooled it
- The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.EBioMedicine · 2020Trial
- Single-Chain Variable Fragment-Based Dot Blot, Single, and Multiple Assays for Rapid SARS-CoV-2 Diagnostics.Journal of AOAC International · 2026Article
- A One-Pot CRISPR/Cas12a-Based Platform for Contamination-Free Nucleic Acid Amplification Detection.Biosensors · 2026Article
- Usabilidade de autoteste de antígeno para COVID-19: fatores associados e desafios relatados.Revista brasileira de enfermagem · 2026Article
- Proteomic Analysis of COVID-19 Infection.Advances in experimental medicine and biology · 2026Article
- Comparing clinical utility of STANDARD M10 rapid rtRT-PCR assay with pooled testing for SARS-CoV-2 screening.Scientific reports · 2025Article
- Post-COVID-19 era sero-surveillance of anti-measles IgM and IgG antibodies among asymptomatic Tanzanian children aged 3 to 15 years Journal.Immunologic research · 2025Article
- Learn from the SARS-CoV-2 nucleic acid test to increase the experience of dealing with the "disease X ".BMC infectious diseases · 2025Article
- Performance assessment of disposable carbon-based immunosensors for the detection of SARS-CoV-2 infections.Scientific reports · 2025Article
- Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022.Emerging infectious diseases · 2024Article
- Article
- Article
- Hierarchical Nanobiosensors at the End of the SARS-CoV-2 Pandemic.Biosensors · 2024Review
- Performance Evaluation of the STANDARD i-Q COVID-19 Ag Test with Nasal and Oral Swab Specimens from Symptomatic Patients.Diagnostics (Basel, Switzerland) · 2024Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.